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Abstract 14 
It has been generally accepted that hydantoin [5-(3,4-dichlorophenyl)methylhydantoin] exerts its anti-15 
enterovirus activity by solely inhibiting viral assembly. However, we here show that hydantoin inhibits 16 
enteroviral RNA synthesis as well as subgenomic replication in a dose-dependent manner. We 17 
demonstrate that inhibition of RNA synthesis is the predominant mechanism of action at relatively high 18 
concentrations of hydantoin. However, at lower concentrations inhibition of viral morphogenesis is the 19 
main mechanism of action. Thus, hydantoin inhibits enteroviral replication by two distinct mechanisms. 20 
   21 
Body text 22 
5-(3,4-dichlorophenyl) methylhydantoin (hydantoin) was first described in 1974 as an in vitro inhibitor of 23 
coxsackievirus-A21 (CV-A21), poliovirus (PV), infectious canine hepatitis and canine distemper virus by 24 
researchers from Eli Lilly (1). The compound was also shown to offer some level of protection against 25 
CV-A21 induced paralysis and mortality in mice. The antiviral effect of hydantoin on PV-1 (strain 26 
Mahoney) replication was later studied in more detail (2). The spectrum of antiviral activity was 27 
determined in a single cycle replication assay and activity was demonstrated against the three PV 28 
serotypes and CV-A21, whereas coxsackievirus-B3 (CV-B3) and human rhinovirus (HRV)-B14 and -29 
A16 proved less susceptible. Time-of-addition studies with end-point titration as read-out, suggested 30 
that hydantoin was an inhibitor of late stage PV replication. Furthermore, it was concluded from Northern 31 
blot analysis that hydantoin, unlike the RNA replication inhibitor guanidine HCl, had no effect on positive-32 
strand viral RNA synthesis. Sucrose density gradient fractionation studies of PV-1-infected cultures 33 
treated with hydantoin revealed an accumulation of the 14S pentamer and 75S pro-capsid assembly 34 
intermediates as well as the presence of a new 110S encapsidation intermediate. In this 110S fraction 35 
VP0 proved to be only partially cleaved into VP2 and VP4, a process known to occur after RNA 36 
encapsidation has taken place (3). These data let the authors to conclude that hydantoin affected viral 37 
encapsidation and maturation of the 110S intermediate. Accumulation of the 110S PV encapsidation 38 
intermediate following treatment with hydantoin was also observed in another study (4). By contrast, in 39 
yet another study the appearance of this intermediate particle was not observed albeit an effect on PV 40 
assembly was further proposed based on data obtained from a cell-free system (5).  41 
We demonstrated recently that a glutathione-depleting molecule (TP219) efficiently blocks enterovirus 42 
morphogenesis (6). In some of our (preliminary) studies hydantoin was used as a reference compound. 43 
Using this molecule, we obtained results that challenged the above mentioned lack of inhibitory activity 44 
on poliovirus RNA replication (which was previously demonstrated by means of Northern blot) (2). To 45 
investigate this further, we studied the effect of a concentration series of hydantoin on viral RNA 46 
synthesis in a single round of viral replication. Briefly, cells were infected with either CV-B3 Nancy, EV-47 
A71 BrCr or PV-1 Sabin (MOI >10) and were treated with four different concentrations (5, 25, 50, 100 48 
µg/ml) of hydantoin or 150 µg/ml of guanidine HCl, a well-known inhibitor of viral RNA replication (7). 49 
Following a seven hours incubation period, intracellular RNA was isolated (Qiagen kit) and viral RNA 50 
levels were quantified by means of a RT-qPCR probe-based assay. In parallel, potential 51 
cytostatic/cytotoxic effects of hydantoin on cell viability was assessed by means of an MTS [3-(4,5-52 
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenol)-2-(4-sulfophenyl)-2H-tetrazolium,innersalt] assay 53 
according to published methods (8). Hydantoin was shown to inhibit in a dose-dependent manner the 54 
accumulation of viral RNA of all three viruses (Fig. 1A-C) without apparent toxicity (Fig. 1D). However, 55 
differences in susceptibility of the different viruses was observed. CV-B3 proved to be relative resistant 56 
to the antiviral effect of hydantoin. EV-A71 however was the most susceptible of the viruses studied as 57 
RNA synthesis was already completely inhibited by hydantoin at a concentration of 25 µg/ml. It was 58 
previously shown that a Q65R amino acid substitution in the PV-1 2C protein conferred partial resistance 59 
to hydantoin (2). Similarly, we here show that hydantoin inhibited wild-type PV-1 RNA replication more 60 
efficiently than replication of the PV-1 2C Q65R variant. Interestingly, this mutation also resulted in a 61 
partial resistance to the viral RNA replication inhibitor Gua HCl, suggesting that this amino acid might 62 
also play a role during viral RNA synthesis which further corroborates the observation that hydantoin 63 
affects viral RNA replication. Thus, whereas it was earlier reported that hydantoin at 50 µg/ml does not 64 
affect viral RNA replication of PV-1 Mahoney (2, 5), we here now demonstrate, using RT-qPCR analysis 65 
in single cycle assays, that hydantoin inhibits enterovirus viral RNA replication in a dose dependent 66 
manner. 67 
To further corroborate the RT-qPCR analysis, we next studied the potential antiviral effect of hydantoin 68 
on PV-1, EV-A71 and CV-B3 subgenomic replicon replication (9-11). Given that in these replicons the 69 
viral structural genes have been replaced by a luciferase gene, any antiviral effect can per definition not 70 
be caused by an effect on assembly. In such case that hydantoin would solely act by blocking viral 71 
morphogenesis and not by targeting viral RNA replication, no effect on replicon replication will be 72 
observed. Briefly, monolayer cultures of BGM or RD cells were transfected with the different replicons 73 
constructs and incubated at 37°C in standard tissue culture medium, supplemented with a particular 74 
concentration of the antiviral compound. Following 12 h of incubation, firefly luciferase activity was 75 
measured with the Steady-Glo Luciferase Assay System (Promega) (Fig. 2). Hydantoin inhibited the 76 
luciferase signal in cells transfected with the EV-A71, PV-1 and CV-B3 constructs in a dose dependent 77 
manner. In analogy with the RT-qPCR analysis, hydantoin inhibited replicons in a comparable manner 78 
whereby the CV-B3 replicon proved to be least sensitive to the antiviral effect of hydantoin and the EV-79 
A71 replicon the most sensitive. Taken together, these data clearly show that hydantoin is an inhibitor 80 
of enteroviral RNA replication. 81 
Since it was previously shown that hydantoin inhibits viral morphogenesis, it might be possible that 82 
hydantoin inhibits enterovirus replication by a dual mechanism of action. To investigate this possibility, 83 
we studied the inhibitory effect of hydantoin on PV-1 replication by measuring intracellular (Fig. 3A) and 84 
extracellular (Fig. 3B) RNA levels and infectious virus particles (Fig. 3C) in a single cycle assay. Gua 85 
HCl completely blocked intracellular viral RNA replication whereas geldanamycin (a known inhibitor of 86 
heat shock protein 90 that was previously reported to inhibit morphogenesis without affecting viral RNA 87 
replication (12)) did not reduce intracellular viral RNA levels (Fig. 3A). In line with the observations 88 
above, both concentrations of 50 and 100 µg/ml hydantoin inhibited viral RNA synthesis albeit to a 89 
different extent. Whereas 50 µg/ml of hydantoin had only little effect on viral RNA synthesis, 100 µg/ml 90 
hydantoin markedly decreased intracellular levels of viral RNA. In parallel, we also assessed the effect 91 
of these compounds on extracellular RNA levels and the formation of infectious virus particles (Fig. 3B 92 
and 3C). As expected, geldanamycin treatment clearly resulted in a comparable reduction of both 93 
extracellular RNA and infectious virus particles, indicating that despite having no effect on intracellular 94 
RNA replication, the formation of infectious virus particles is severely hampered. Similar to Gua HCl 95 
treatment, a concentration of 100 µg/ml hydantoin completely blocked both extracellular RNA levels and 96 
infectious virus particles as well. Thus, at this concentration the predominant mechanism of action is 97 
inhibition of viral RNA replication. In contrast, 50 µg/ml hydantoin clearly reduced extracellular RNA 98 
levels and the amount of infectious virus particles despite having only little effect on intracellular RNA 99 
replication. Thus, at 50 µg/ml hydantoin, the predominant mechanism of action of hydantoin appears to 100 
be inhibition of virus morphogenesis. Interestingly, at this concentration the effect on extracellular RNA 101 
levels was less pronounced than the effect on infectious virus particles production, suggesting that the 102 
extracellular RNA detected might not have originated form infectious virus.  103 
Taken together, we provide conclusive evidence that the antiviral compound hydantoin has a dual 104 
mechanism of action. At 50 µg/ml, the predominant mechanism of action is the inhibition of 105 
morphogenesis of infectious virus particles and RNA synthesis is little affected. This likely explains why 106 
it was earlier reported that hydantoin exclusively inhibits viral morphogenesis, since all the experiments 107 
were performed using concentrations of 50 µg/ml. However, we now show that at higher concentrations 108 
hydantoin also inhibits viral RNA synthesis. A tight link between viral RNA replication and the process 109 
of morphogenesis has been described before. For instance, a quasi-infectious chimeric virus that 110 
replicates it’s genome with wildtype kinetics but has an impaired encapsidation phenotype, could be 111 
rescued by a single mutation in protein 2C, a protein that is an essential part of the viral replication 112 
complex (13). In the same study, biochemical assays provided strong evidence for a direct interaction 113 
between protein 2C and the capsid protein VP3. In a later study by the same laboratory encapsidation 114 
defective PV was generated by means of alanine-scanning mutagenesis of 2C, demonstrating the role 115 
of this viral protein in morphogenesis (14). Moreover, the defect could be rescued by suppressor 116 
mutations in either 2C itself or in VP1/VP3, demonstrating a functional interaction between 2C and the 117 
capsid proteins. Within this context, it might not be surprising that hydantoin might affect both RNA 118 
replication and virus morphogenesis. The precise mechanisms by which the compound inhibits viral 119 
RNA synthesis and how it exerts its dual mode of action remain to be studied. 120 
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Bullet points 129 
• Hydantoin was earlier reported to solely inhibit enterovirus morphogenesis. 130 
• Hydantoin has a dual mechanism of antiviral action that involves inhibition of morphogenesis 131 
and RNA replication 132 
• The predominant mechanism of inhibition is determined by the concentration of hydantoin.   133 
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Legend to Figures 
Figure 1. Hydantoin inhibits viral RNA replication. Cell cultures were infected with (A) CV-B3, (B) EV-
A71 or (C) PV-1 WT and PV-1 2C Q65R and treated with 150 µg/ml Gua HCl or the indicated 
concentration of hydantoin. Intracellular viral RNA was isolated seven hours post infection and quantified 
by means of RT-qPCR. (D) BGM cell viability with MTS assay after incubation with a concentration 
series of hydantoin. The dotted line indicates the untreated control. All data are mean values ± SD of ≥3 
individual measurements. 
Figure 2. Hydantoin inhibits subgenomic replicons. Cell cultures were transfected with viral replicons of 
PV-1, EV-A71 and CV-B3 and treated with 96 µg/ml Guanidine HCl or 10, 50 or 100 µg/ml hydantoin. 
Following 12 hours of incubation luciferase activity was measured. All data are mean values ± SD of ≥3 
individual measurements.  
Figure 3. Hydantoin has a dual mechanism of action. BGM cell cultures were infected with PV-1 at an 
MOI >10. After an incubation period of one hour, the virus was aspirated and replaced with medium 
containing the appropriate compound. At 8 hours post infection both the intracellular (A) and extracellular 
(B) PV-1 RNA content was determined using qPCR. (C) In parallel, cell cultures were infected with PV-
1 at a MOI of 5. After an incubation period of one hour, the virus was aspirated and replaced with medium 
containing the appropriate compound. At 8 hours post infection, cultures were frozen and subjected to 
three rounds of freeze-thawing. Virus titers were determined using end-point titration. The dotted line 
indicates the untreated control. All data are mean values ± SD of ≥3 individual measurements  
 



